Anti-vascular endothelial growth factor injection may be an important adjunct tosystemic therapy in eyes with with sympathetic ophthalmia-associated CNV.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Choroidal neovascular membrane (CNV) is a very rare complication in patients with sympathetic ophthalmia.
📊
Key Findings & Data:We hereby report a38-year-old man who developed a type 2 CNV in his only seeing (left) eye while under systemic steroid treatment.
💡
Conclusion & Impact:Anti-vascular endothelial growth factor injection may be an important adjunct tosystemic therapy in eyes with with sympathetic ophthalmia-associated CNV.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Choroidal neovascular membrane (CNV) is a very rare complication in patients with sympathetic ophthalmia. We hereby report a38-year-old man who developed a type 2 CNV in his only seeing (left) eye while under systemic steroid treatment. Systemic therapywas revised and a total of 5 intravitreal aflibercept injections (2 mg each) were administered over a period of 8 months. Good anatomicand functional outcome was noted at the last visit. Anti-vascular endothelial growth factor injection may be an important adjunct tosystemic therapy in eyes with with sympathetic ophthalmia-associated CNV.
🔖
Cite This Article
AYHAN, Z., BAJİNA, M. S., IPEK, Ş. C., SAATÇİ, A. O. (2022). Intravitreal Aflibercept as an Adjunct to Systemic Therapy in a Case of Choroidal Neovascular Membrane Associated with Sympathetic Ophthalmia. Türk Oftalmoloji Dergisi, Cilt: 48 - Sayı: 4, 209–211. https://ajindex.com/articles/637776
Lai TYY, Staurenghi G, Lanzetta P, Holz FG, Melissa Liew SH, DessetBrethes S, Staines H, Hykin PG; MINERVA study group. Efficacy and safety of ranibizumab for the treatment of choroidal neovascularization due to uncommon cause: Twelve-Month Results of the MINERVA Study. Retina. 2018;38:1464-1477. Bhende M. AAS. Management of Inflammatory CNV. In: Biswas J. MP, ed. Uveitis: An Update. New Delhi; Springer; 2016:109-117. D’Ambrosio E, Tortorella P, Iannetti L. Management of uveitis-related choroidal neovascularization: from the pathogenesis to the therapy. J Ophthalmol. 2014;2014:450428. Battaglia Parodi M, Iacono P, Verbraak FD, Bandello F. Antivascular endothelial growth factors for inflammatory chorioretinal disorders. Dev Ophthalmol. 2010;46:84-95.
Davis JL, Madow B, Cornett J, Stratton R, Hess D, Porciatti V, Feuer WJ. Scale for photographic grading of vitreous haze in uveitis. Am J Ophthalmol. 2010;150:637-641.
Bansal R, Bansal P, Gupta A, Gupta V, Dogra MR, Singh R, Katoch D. Diagnostic Challenges in Inflammatory Choroidal Neovascular Membranes. Ocul Immunol Inflamm. 2017;25:554-562.
Baxter SL, Pistilli M, Pujari SS, Liesegang TL, Suhler EB, Thorne JE, Foster CS, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Kempen JH. Risk of choroidal neovascularization among the uveitides. Am J Ophthalmol. 2013;156:468-477.
Bom S, Young S, Gregor Z, Lightman S. Surgery for choroidal neovascularization in sympathetic opthalmia. Retina. 2002;22:109-111.
Julian K, Terrada C, Fardeau C, Cassoux N, Francais C, LeHoang P, Bodaghi B. Intravitreal bevacizumab as first local treatment for uveitis-related choroidal neovascularization: long-term results. Acta Ophthalmol. 2011;89:179-184.
Vianna RN, Ozdal P, Souza Filho JP, Deschenes J. Choroidal neovascularization associated with sympathetic ophthalmia: case report. Arq Bras Oftalmol. 2005;68:397-400.
Kinge B, Syrdalen P, Bjornsson OM. Photodynamic therapy for choroidal neovascularization secondary to sympathetic ophthalmia. Retina. 2005;25:375-377.
Borkowski LM, Weinberg DV, Delany CM, Milsow L. Laser photocoagulation for choroidal neovascularization associated with sympathetic ophthalmia. Am J Ophthalmol. 2001;132:585-587.
Kilmartin DJ, Forrester JV, Dick AD. Cyclosporine-induced resolution of choroidal neovascularization associated with sympathetic ophthalmia. Arch Ophthalmol. 1998;116:249-250.
Carney MD, Tessler HH, Peyman GA, Goldberg MF, Williams DP. Sympathetic ophthalmia and subretinal neovascularization. Ann